Morphic Therapeutic, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- $2.8B
- Website
- http://www.morphictx.com
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Phase 2
Recruiting
- Conditions
- Inflammatory Bowel DiseasesCrohn's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Morphic Therapeutic, Inc
- Target Recruit Count
- 210
- Registration Number
- NCT06226883
- Locations
- 🇪🇸
Clinical Study Site, Valencia, Spain
🇬🇪Clinical Study Site 2, Tbilisi, Georgia
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
Phase 2
Active, not recruiting
- Conditions
- Inflammatory Bowel DiseasesColitis, Ulcerative
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Morphic Therapeutic, Inc
- Target Recruit Count
- 282
- Registration Number
- NCT05611671
- Locations
- 🇨🇳
Clinical Study Site, Taipei, Taiwan
A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Morphic Therapeutic, Inc
- Target Recruit Count
- 39
- Registration Number
- NCT05291689
- Locations
- 🇵🇱
Clinical Study Site, Łódź, Poland
Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Morphic Therapeutic, Inc
- Target Recruit Count
- 67
- Registration Number
- NCT04580745
- Locations
- 🇺🇸
Medpace, Cincinnati, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath